22/01/2019 - 11:09

MGC gets green light for cannabis dementia drug trial

22/01/2019 - 11:09

Bookmark

Save articles for future reference.

MGC Pharmaceuticals has secured approval from Australia’s Therapeutic Goods Administration to start the Phase IIB clinical trial of its CogniCann medical cannabis treatment for dementia and Alzheimer’s patients. The company’s manufacturing facility in Ljubljana, Slovenia, has also secured a permit to extract and develop its own Phytocannabinoid active pharmaceutical ingredients.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options